ClinicalTrials.gg
CompletedNCT07799090Updated Sep 2, 2026

Pharmacokinetic Study of GB-5001A 280 mg Long Acting Injection, in Comparison With the Comparator Drug Aricept® 5 mg and Aricept® 10 mg Film-coated Tablet in Healthy Subjects

A Phase 1 interventional study of GB-5001A 280 mg long acting Injection and Aricept® 5 mg film-coated tablet in Bioavailability Study on Healthy Volunteers, sponsored by G2GBio, Inc.. Completed at 1 site in Indonesia. Open to male participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by G2GBio, Inc. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Aug 2025, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
19 Years to 45 Years
Sex
Male
01

Study summary

This study is to find out whether the bioavailability of GB-5001A 280 mg Injection is compared to the comparator drug of Aricept® 5 mg and Aricept® 10 mg which are Film-Coated Tablet when administered in healthy subjects. Also to monitor the adverse events and to ensure the safety of the subjects.

02

Conditions studied

  • Bioavailability Study on Healthy Volunteers

Keywords

  • Donepezil
  • Aricept
  • Bioavailability
  • Pharmacokinetics
03

In context

Lead sponsor

G2GBio, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to participate, communicate well with the investigators and willing to provide written to participate in the study.
  • Healthy male subjects with absence of significant disease or abnormal laboratory values on laboratory evaluation, medical history or physical examination during the screening and could be considered healthy based on the evaluation.
  • Aged 19-45 years inclusive.
  • Non-smokers.
  • within 18.5 to 30.0 kg/m2.
  • Vital signs (after 10 minutes rest) must be within the range (i.e Systolic blood pressure 100 - 129 mmHg; Diastolic blood pressure 60 - 84 mmHg)
  • Willing to practice abstention or non-hormonal during the study.

Exclusion criteria

Exclusion Criteria:

  • History of allergy or or to Donepezil or other allied drugs.
  • Any major illness in the past 90 days or ongoing chronic medical illness.
  • Presence of any clinically significant abnormal values during screening e.g. significant abnormality of liver function test (, ALT, alkaline phosphatase, total , direct bilirubin ≥ 1.5 ), renal failure or renal function test (serum creatinine concentration > 1.4 mg/dL and ureum ≥ 1.5 ULN), etc.
  • Positive surface antigen (HBsAg), anti-, or anti-.
  • Clinically significant hematology abnormalities.
  • Clinically significant 12-Lead (12-Lead ECG) abnormalities.
  • Any surgical or medical condition (present or history) which might significantly alter the absorption, distribution, metabolism or excretion of the study drug, e.g. gastrointestinal disease including gastric or duodenal ulcers or history of gastric surgery.
  • Past history of anaphylaxis or angioedema.
  • History of drug or alcohol abuse within 12 months prior to screening for this study.
  • Participation in any clinical trial within the past 90 days calculated from the last visit until this study's first dosing day.
  • History of any bleeding or coagulative disorders.
  • Presence of difficulty in accessibility of veins in left or right arm.
  • A donation or significant blood loss within 90 days before this study's first dosing day.
  • Intake of any prescription drug (especially Donepezil), non prescription drug (including hormonal ), food supplements or herbal medicines within 28 days of this study's first dosing day.
  • History of allergic contact dermatitis.
  • History of muscle weakness.
  • History of myasthenia gravis.
  • History of peptic ulcer or Gastritis.
  • History of seizure.
  • History of bronchitis, asthma, or lung infections.
  • Bradycardia was detected during the screening process.
  • Difficulty in swallowing capsule or tablet.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    GB-5001A

    GB-5001A 280 mg long acting Injection

    Drug: GB-5001A 280 mg long acting Injection

  • Experimental
    Aricept & GB-5001A

    Active Comparator: Aricept® 5 mg tablet and Experimental: GB 5001A 280 mg long acting Injection

    Drug: GB-5001A 280 mg long acting Injection · Drug: Aricept® 5 mg film-coated tablet

  • Active comparator
    Aricept

    Aricept® 5 mg tablet and Aricept® 10 mg tablet

    Drug: Aricept® 5 mg film-coated tablet · Drug: Aricept® 10 mg film-coated tablet

Interventions

  • DrugGB-5001A 280 mg long acting Injection

    Depending on the cohort, doses will be varied to administer.

  • Aricept® (donepezil hydrochloride) 5 mg film-coated tablet administered orally as an active comparator

  • Aricept® (donepezil hydrochloride) 10 mg film-coated tablet administered orally as an active comparator

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameter

    Peak plasma concentration during steady state (Cmax,ss)

    Time frame: 204 days of G1, 226 days of G2, 40 days of G3

  2. Pharmacokinetic parameter

    Minimum plasma concentration during steady state (Cmin,ss)

    Time frame: 204 days of G1, 226 days of G2, 40 days of G3

  3. Pharmacokinetic parameter

    Average drug concentration at steady state (Cav,ss)

    Time frame: 204 days of G1, 226 days of G2, 40 days of G3

  4. Pharmacokinetic parameter

    Time to maximum concentration at steady state (Tmax,ss)

    Time frame: 204 days of G1, 226 days of G2, 40 days of G3

  5. Pharmacokinetic parameter

    Area under the plasma concentration versus time curve during a dosage interval at steady state (AUCτ,ss)

    Time frame: 204 days of G1, 226 days of G2, 40 days of G3

  6. Pharmacokinetic parameter

    Area under the plasma concentration versus time curve extrapolated to infinite time (AUCinf)

    Time frame: 204 days of G1, 226 days of G2, 40 days of G3

  7. Pharmacokinetic parameter

    Apparent total body clearance of drug from plasma after oral administration at steady state (CLss/F)

    Time frame: 204 days of G1, 226 days of G2, 40 days of G3

  8. Pharmacokinetic parameter

    Apparent volume of distribution at steady state (Vss/F)

    Time frame: 204 days of G1, 226 days of G2, 40 days of G3

  9. Pharmacokinetic parameter

    Plasma half life (t1/2)

    Time frame: 204 days of G1, 226 days of G2, 40 days of G3

Secondary outcomes

  1. Adverse events

    Number of subjects and Incidences with adverse events by Study arm.

    Time frame: Day 1 to Day 226

07

Study locations

1 site
  • PT Equilab International
    Jakarta, South Jakarta 12430, Indonesia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Apr 2026, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2026
First posted
Sep 2, 2026
StartActual
Aug 12, 2025
Primary completionActual
Apr 15, 2026
CompletionActual
Apr 15, 2026
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07799090
Lead sponsor
G2GBio, Inc.
Collaborators
PT Equilab International
Responsible party
Sponsor
First posted
Sep 2, 2026
Start date
Aug 12, 2025
Primary completion
Apr 15, 2026
Completion
Apr 15, 2026
Last update
Sep 2, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion